Interventional device developer Boston Scientific said that the U.S. Food and Drug Administration has approved extending the shelf life of its Taxus Express² paclitaxel-eluting coronary stent system from 12 months to 18 months.
The extended expiration date applies to all available sizes of the Taxus stent for sale in the U.S., according to the Natick, MA-based firm.
By AuntMinnie.com staff writers
January 18, 2007
Related Reading
Boston Scientific launches Promus, January 11, 2007
Boston Scientific buys EndoTex, January 4, 2007
Boston Scientific receives FDA nod for FilterWire EZ, December 14, 2006
Boston Scientific, GE integrate informatics apps, November 9, 2006
Boston to bring Liberte to Japan, November 6, 2006
Copyright © 2007 AuntMinnie.com